ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-5268ometendo-5268Research ArticleСтатьиArticlesПротивопоказания к приему метформинадолжны быть пересмотреныProtivopokazaniya k priemu metforminadolzhny byt' peresmotreny---20061509200633№3 (2006)5961Copyright © - -., 20062006- -.- -.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/5268ReferencesMetformin`s contraindications should be contraindicated. James McCormack, Kevin Jons and Hugh Tildesley. Faculty of Pharmaceutical Sciences, University of British Columbia (McCormack); and Division of Endocrinology, St. Paul`s Hospital, Vancouver, BC (Johns, Tildesley). CMAJ. August 30. 2005; 173 (5).Metformin`s contraindications should be contraindicated. James McCormack, Kevin Jons and Hugh Tildesley. Faculty of Pharmaceutical Sciences, University of British Columbia (McCormack); and Division of Endocrinology, St. Paul`s Hospital, Vancouver, BC (Johns, Tildesley). CMAJ. August 30. 2005; 173 (5).UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-65.UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-65.Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao R H. Evalution of prescribing practices:risk of lactic acidosis with metformin therapy. Arch Intern Med. 2002; 162:434-7.Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao R H. Evalution of prescribing practices:risk of lactic acidosis with metformin therapy. Arch Intern Med. 2002; 162:434-7.McCormac J, Greenhalgh T. Seeing what you want to see in randomized controlled trials:versions and perversions of UKPDS data. BMJ. 2000;320:1720-3.McCormac J, Greenhalgh T. Seeing what you want to see in randomized controlled trials:versions and perversions of UKPDS data. BMJ. 2000;320:1720-3.Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Arch Intern Med. 2003;163:2594-602.Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Arch Intern Med. 2003;163:2594-602.Brown LB, Pedula K, Barzilay J, Herson M K, Latare P. Lactic acidosis rates in type 2 diabetes. Diabetes Care. 1998;21:1659-63.Brown LB, Pedula K, Barzilay J, Herson M K, Latare P. Lactic acidosis rates in type 2 diabetes. Diabetes Care. 1998;21:1659-63.Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care. 1997;20:925-8.Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care. 1997;20:925-8.Misbin RI, Green L, Stadel BV, Gueriguan JL, Gabbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med. 1998; 338:265-6.Misbin RI, Green L, Stadel BV, Gueriguan JL, Gabbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med. 1998; 338:265-6.
The authors declare that there are no conflicts of interest present.